Home > Cardiology > AHA 2020 > COVID-19 and Influenza > High-dose influenza vaccine in patients with CVD

High-dose influenza vaccine in patients with CVD

Presented By
Prof. Orly Vardeny, University of Minnesota Medical School, USA
Conference
AHA 2020
Trial
Phase 4, INVESTED

A high-dose, trivalent influenza vaccine was not more effective than the standard-dose quadrivalent vaccine at reducing the risk of death or hospitalisation for heart-related or lung-related causes in patients with a history of recent hospitalisation for acute myocardial infarction (MI) or heart failure (HF). This was the main conclusion from the INVESTED study [1,2].

In patients with underlying cardiovascular disease, influenza is temporally associated with cardiopulmonary morbidity and mortality, including MI, hospitalisations for HF, and death. Influenza vaccination reduces adverse clinical outcomes and is recommended annually. However, individuals with cardiovascular disease often mount a less effective vaccine-induced protective response [2]. The same holds true for older patients (aged ≥65 years) for whom a high-dose vaccine is approved in the USA.

The INVESTED study (



Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on